Does anyone else think this is outrageous? “Glaxo Is Testing Paxil on 7-Year-Olds Despite Well Known Suicide Risks”

It was established years ago that Paxil carries a risk of suicide in children and teens, but GlaxoSmithKline (GSK) has for the last 18 months been conducting a study of the antidepressant in kids as young as seven — in Japan. It’s not clear why the company would want to draw more attention to its already controversial pill, but it appears as if GSK might be hoping to see a reduced suicide risk in a small population of users — a result the company could use to cast doubt on the Paxil-equals-teen-suicide meme that dominates discussion of the drug.

Australia’s growing drug problem—Elderly overprescribed antidepressants

Older Australians are being overprescribed medications for depression, according to a study by University of Queensland researchers published today in the Australian and New Zealand Journal of Psychiatry.

The New American: Psychiatry Enters Dangerous Territory—Newly proposed disorders and the threat to personal liberty

The new fourth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the American Psychiatric Association may define several new psychiatric disorders. Some of these do not sound like varieties of mental illness at all, but rather opinions and attitudes. What would “oppositional defiant disorder,” for example, represent?

Huffington Post: Poor Kids far more likely to be prescribed psychiatric drugs

Children covered by Medicaid are far more likely to be prescribed antipsychotic drugs than children covered by private insurance, and Medicaid-covered kids have a higher likelihood of being prescribed antipsychotics even if they have no psychotic symptoms. This is reported in the May19, 2010 Journal of American Medical Association (JAMA) article, “Studies Shed Light on Risks and Trends in Pediatric Antipsychotic Prescribing.”

A good start: Antipsychotic drug maker to pay half billion in fines for illegal marketing

Drugmaker AstraZeneca has agreed to pay $520 million to settle federal investigations into marketing practices for its schizophrenia drug Seroquel. This makes AstraZeneca the fourth big drug company in the last three years to admit to federal charges of illegal marketing of antipsychotic drugs.

CCHR International

News